German pharma major Boehringer Ingelheim, one of the world's largest privately held drugmakers, has discontinued a Phase III study testing its experimental aldosterone synthase inhibitor vicadrostat ...

Patient experience data (PED) are direct insights that patients provide on their symptoms, quality of life, treatment preferences and unmet ...

Generating good-quality patient experience data (PED) is becoming increasingly important for medicine development, and ...

The label expansion for Boehringer Ingelheim’s Hernexeos was made under an FDA pilot program that accelerates regulatory review of products with national interest. The daily pill is now approved as a ...

For many deaf people, medicine package inserts may look readable-but remain silent. A sign language avatar developed with ...

INGELHEIM, Germany & SAN FRANCISCO--(BUSINESS WIRE)--Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and ...

BIBERACH, Germany--(BUSINESS WIRE)--Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in ...

Innovation is the lifeblood of progress and can occasionally be the result of a flash of individual brilliance. However, in drug development, it often can’t be rushed. Researchers need time not only ...

In Argentina, employees from partnered with doctors to bring digital healthcare solutions to remote communities, improving the quality and follow-up of medical records to transform patient ...

Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a research & development press conference entitled ‘Transcending Disease Boundaries’, at its global ...

Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...

By Sahil Pandey Sept 2 (Reuters) - AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and ...